Revenue: As of FY2025 Q2, the actual value is USD 29.04 M.EPS: As of FY2025 Q2, the actual value is USD 0.5.<h3>Segment Revenue</h3><ul><li>Income from Purchased Receivables under the EIR Method: $6,007,000 for the three months ended June 30, 2025, and $12,077,000 for the six months ended June 30, 2025.</li><li>Income from Purchased Receivables under the Cost Recovery Method: $1,743,000 for the three months ended June 30, 2025, and $7,268,000 for the six months ended June 30, 2025.</li><li>Revenue from Contracts with Customers: $5,025,000 for the three months ended June 30, 2025, and $9,025,000 for the six months ended June 30, 2025.</li><li>Revenue Recognized under Units-of-Revenue Method: $354,000 for the three months ended June 30, 2025, and $671,000 for the six months ended June 30, 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: $9,191,000 for the three months ended June 30, 2025, and $11,558,000 for the six months ended June 30, 2025.</li><li>General and Administrative Expenses: $7,802,000 for the three months ended June 30, 2025, and $15,948,000 for the six months ended June 30, 2025.</li><li>Research and Development Expenses: $69,000 for the three months ended June 30, 2025, and $1,362,000 for the six months ended June 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by Operating Activities: $8,668,000 for the six months ended June 30, 2025.</li><li>Net Cash Used in Investing Activities: - $26,674,000 for the six months ended June 30, 2025.</li><li>Net Cash Used in Financing Activities: - $9,925,000 for the six months ended June 30, 2025.</li></ul><h3>Unique Metrics</h3><ul><li>Investment in Equity Securities: $8,801,000 as of June 30, 2025.</li><li>Intangible Assets, Net: $45,434,000 as of June 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue its strategy as a biotech royalty aggregator, focusing on acquiring rights to future milestones, royalties, and commercial payments associated with partnered therapeutic candidates.</li><li>Non-Core Business: The company is involved in several acquisitions, including Turnstone, ESSA, LAVA, and HilleVax, which are expected to close in the near future, expanding its portfolio and potential revenue streams.</li></ul>

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B | 10-Q: FY2025 Q2 Revenue: USD 29.04 M